Cannabis-Based drug BRC-002 enters first human safety trials

NCT ID NCT07699120

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Biopharmaceutical Research Company Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 1 study evaluates the safety and tolerability of BRC-002, an investigational cannabis-derived botanical drug, in healthy adults aged 18 to 55. Researchers will also examine how the body processes the drug and whether food affects its absorption. The results will guide future dosing and development for patient populations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BRC-002 (cannabis-derived botanical drug)
What this could lead to: If successful, this study could support further development of BRC-002 as a potential treatment for various conditions.
What could go wrong: This is an early phase 1 trial in healthy volunteers, so results may not predict effects in patients. Side effects or lack of tolerability could halt progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT PARTICIPANTS

Contacts and locations

Show contact details

Locations

Bio Pharma Research Inc.

Toronto, Ontario, M9L 3A2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.